• Molecular biologist with expertise at the interface of genomics, chemical biology and drug discovery. • Goal-oriented drug hunter with small molecule drug discovery experience across indications, including oncology, chronic inflammation, autoimmune diseases, Sickle Cell disease and muscular dystrophy. • Drug discovery leader that has successfully helped multiple start-up companies grow from company concepts into clinical-stage, publicly- traded companies ($SYRS, $FULC, $KRON). • Broad experience covering a range of disciplines including molecular biology, drug discovery, stem cell biology, in vitro modeling, in vivo modeling, biochemistry, computational/systems biology, genomics and chemistry. • Published 25 scientific manuscripts in high impact journals including Cell, Science and Nature and co-inventor on four issued US patents. • Training at Cornell University and the Whitehead Institute at MIT. Work I was involved in at MIT formed the foundation of the company Syros Pharmaceuticals, where I was an early consultant and founding scientist. • Biology lead of the Sickle Cell program at Fulcrum Therapeutics that identified EED as a novel target for fetal hemoglobin reactivation and developed the Discovery Candidate FTX-6058/Pociredir. Currently in Ph1b/Ph2 trials and has demonstrated proof of biology in humans. • Led multiple programs from early Discovery to Development Candidate nomination in Sickle Cell disease, multiple myeloma and Sjögren’s disease. Publications https://www.ncbi.nlm.nih.gov/pubmed?term=rahl%20pb%5BAuthor %5D
